Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Fibroids.

Abstract Study Objective To study the effects of ulipristal acetate (UPA) on adenomyosis-associated clinical symptoms. Design A retrospective, single-center observational study (Canadian Task Force classification II-2). Setting A university tertiary referral center. Patients Premenopausal women (163) with adenomyosis and symptomatic uterine myomas (41 patients, A + F group) versus a control group with only myomas (122 patients, F group) treated with the first course of UPA. Interventions This was a retrospective study to assess the effects of a 12-week course of UPA (5 mg/d). Measurements and Main Results Clinical symptoms including bleeding control, amenorrhea, pain outcomes, and self-perceived severity of the disease and quality of life. Amenorrhea was present in 90.4% of the A + F group compared with 77.6% in the F group (p = .0017). Optimal bleeding control was significantly higher in the adenomyosis group (pictorial blood loss assessment chart  Conclusion Treatment with UPA led to a significant reduction in the clinical symptoms of adenomyosis (bleeding and pain) and achieved a high rate of amenorrhea in a cohort of women with concomitant uterine myomas. Despite the limitations of the study, our results showed that UPA might be a good alternative treatment for adenomyosis.